Loading…
Reported covered position: Staff Assistant, Rep. Todd Young; Legislative Correspondent/Press Assistant, Rep. Todd Young; Legislative Assistant, Rep. Todd Young; Legislative Assistant, U.S. Senator Todd Young; Health Policy Director, U.S. Senator Todd Young
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
American Rescue Plan Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act. * Issues related to the Centers for Medicare & Medicaid Services Maryland Total Cost of Care Model.
Source: Senate LDA
American Rescue Plan Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Telehealth Modernization Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021.
Telehealth Modernization Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021.
Postal Service Reform Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to S. 1720/H.R. 3076, the Postal Service Reform Act of 2022.
Postal Service Reform Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to S. 1720/H.R. 3076, the Postal Service Reform Act of 2022.
Improving Seniors’ Timely Access to Care Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074, To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act.
Improving Seniors’ Timely Access to Care Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act. * Issues related to the Centers for Medicare & Medicaid Services Maryland Total Cost of Care Model.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act. * Issues related to the Centers for Medicare & Medicaid Services Maryland Total Cost of Care Model.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074, To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act.
Improving Social Determinants of Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Addressing Social Determinants in Medicare Advantage Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074, To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act.
Inflation Reduction Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act. * Issues related to the Centers for Medicare & Medicaid Services Maryland Total Cost of Care Model.
Inflation Reduction Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074, To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act.
Inflation Reduction Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Inflation Reduction Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021.
Restoring Hope for Mental Health and Well-Being Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021.
Mental Health Matters Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021.
Improving Social Determinants of Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Prescription Pricing for the People Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021.
CONNECT for Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
CONNECT for Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021.
Postal Service Reform Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to S. 1720/H.R. 3076, the Postal Service Reform Act of 2022.
Postal Service Reform Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to S. 1720/H.R. 3076, the Postal Service Reform Act of 2022.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act. * Issues related to the Centers for Medicare & Medicaid Services Maryland Total Cost of Care Model.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074, To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act.
Improving Seniors’ Timely Access to Care Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074, To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act.
Improving Seniors’ Timely Access to Care Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act. * Issues related to the Centers for Medicare & Medicaid Services Maryland Total Cost of Care Model.
Telehealth Extension and Evaluation Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act. * Issues related to the Centers for Medicare & Medicaid Services Maryland Total Cost of Care Model.
Telehealth Extension and Evaluation Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074, To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act.
Telehealth Modernization Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021.
Telehealth Modernization Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Affordable Insulin Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Affordable Insulin Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021.
Pharmacy Benefit Manager Transparency Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021.
Improving Health Insurance Affordability Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
American Rescue Plan Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
American Rescue Plan Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to S.909, The Prescription Drug Price Relief Act; S. 908, The Medicare Drug Price Negotiation Act; and S. 920, The Affordable and Safe Prescription Drug Importation Act. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues retated to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
American Rescue Plan Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
American Rescue Plan Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Telehealth Modernization Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Telehealth Modernization Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Telehealth Modernization Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Telehealth Modernization Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to S.909, The Prescription Drug Price Relief Act; S. 908, The Medicare Drug Price Negotiation Act; and S. 920, The Affordable and Safe Prescription Drug Importation Act. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues retated to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
Lower Costs, More Cures Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to S.909, The Prescription Drug Price Relief Act; S. 908, The Medicare Drug Price Negotiation Act; and S. 920, The Affordable and Safe Prescription Drug Importation Act. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues retated to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
Lower Costs, More Cures Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Ensuring Seniors Access to Local Pharmacies Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* H.R 2166/S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. * H.R. 2608, the Ensuring Seniors Access to Local Pharmacies Act of 2021. * H.R. 2846, the Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173, the Improving Seniors Timely Access to Care Act of 2021 * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Policies that impact public programs payments for high cost drugs including gene therapies. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* H.R 2166/S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. * H.R. 2608, the Ensuring Seniors Access to Local Pharmacies Act of 2021. * H.R. 2846, the Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173, the Improving Seniors Timely Access to Care Act of 2021 * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Policies that impact public programs payments for high cost drugs including gene therapies. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Elijah E. Cummings Lower Drug Costs Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to S.909, The Prescription Drug Price Relief Act; S. 908, The Medicare Drug Price Negotiation Act; and S. 920, The Affordable and Safe Prescription Drug Importation Act. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues retated to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
Elijah E. Cummings Lower Drug Costs Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Elijah E. Cummings Lower Drug Costs Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Elijah E. Cummings Lower Drug Costs Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Postal Service Reform Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to S. 1720/H.R. 3076, the Postal Service Reform Act of 2021.
Postal Service Reform Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to S. 1720/H.R. 3076, the Postal Service Reform Act of 2021.
Improving Seniors’ Timely Access to Care Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* H.R 2166/S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. * H.R. 2608, the Ensuring Seniors Access to Local Pharmacies Act of 2021. * H.R. 2846, the Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173, the Improving Seniors Timely Access to Care Act of 2021 * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Policies that impact public programs payments for high cost drugs including gene therapies. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Improving Seniors’ Timely Access to Care Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* H.R 2166/S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173, the Improving Seniors Timely Access to Care Act of 2021. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Policies that impact Medicare vision, dental, and hearing benefits. * Policies that impact public programs payments for high cost drugs including gene therapies. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. Con Res 14 and the impact on the expansion of Medicare benefits.
Improving Seniors’ Timely Access to Care Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173/S.3018, the Improving Seniors Timely Access to Care Act of 2021 * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Improving Seniors’ Timely Access to Care Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173/S.3018, the Improving Seniors Timely Access to Care Act of 2021 * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173/S.3018, the Improving Seniors Timely Access to Care Act of 2021 * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* H.R 2166/S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173, the Improving Seniors Timely Access to Care Act of 2021. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Policies that impact Medicare vision, dental, and hearing benefits. * Policies that impact public programs payments for high cost drugs including gene therapies. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. Con Res 14 and the impact on the expansion of Medicare benefits.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* H.R 2166/S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. * H.R. 2608, the Ensuring Seniors Access to Local Pharmacies Act of 2021. * H.R. 2846, the Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173, the Improving Seniors Timely Access to Care Act of 2021 * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Policies that impact public programs payments for high cost drugs including gene therapies. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173/S.3018, the Improving Seniors Timely Access to Care Act of 2021 * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Infrastructure Investment and Jobs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Improving Social Determinants of Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Improving Social Determinants of Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Improving Social Determinants of Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Improving Social Determinants of Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to S.909, The Prescription Drug Price Relief Act; S. 908, The Medicare Drug Price Negotiation Act; and S. 920, The Affordable and Safe Prescription Drug Importation Act. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues retated to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
Addressing Social Determinants in Medicare Advantage Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* H.R 2166/S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173, the Improving Seniors Timely Access to Care Act of 2021. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Policies that impact Medicare vision, dental, and hearing benefits. * Policies that impact public programs payments for high cost drugs including gene therapies. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. Con Res 14 and the impact on the expansion of Medicare benefits.
Addressing Social Determinants in Medicare Advantage Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173/S.3018, the Improving Seniors Timely Access to Care Act of 2021 * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Addressing Social Determinants in Medicare Advantage Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* H.R 2166/S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. * H.R. 2608, the Ensuring Seniors Access to Local Pharmacies Act of 2021. * H.R. 2846, the Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173, the Improving Seniors Timely Access to Care Act of 2021 * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Policies that impact public programs payments for high cost drugs including gene therapies. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Addressing Social Determinants in Medicare Advantage Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173/S.3018, the Improving Seniors Timely Access to Care Act of 2021 * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Inflation Reduction Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173/S.3018, the Improving Seniors Timely Access to Care Act of 2021 * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Inflation Reduction Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Inflation Reduction Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173/S.3018, the Improving Seniors Timely Access to Care Act of 2021 * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Inflation Reduction Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Inflation Reduction Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Improving Social Determinants of Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Improving Social Determinants of Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Improving Social Determinants of Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Improving Social Determinants of Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to S.909, The Prescription Drug Price Relief Act; S. 908, The Medicare Drug Price Negotiation Act; and S. 920, The Affordable and Safe Prescription Drug Importation Act. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues retated to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
CONNECT for Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
CONNECT for Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
CONNECT for Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to S.909, The Prescription Drug Price Relief Act; S. 908, The Medicare Drug Price Negotiation Act; and S. 920, The Affordable and Safe Prescription Drug Importation Act. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues retated to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
CONNECT for Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Postal Service Reform Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to S. 1720/H.R. 3076, the Postal Service Reform Act of 2021.
Postal Service Reform Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to S. 1720/H.R. 3076, the Postal Service Reform Act of 2021.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* H.R 2166/S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. * H.R. 2608, the Ensuring Seniors Access to Local Pharmacies Act of 2021. * H.R. 2846, the Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173, the Improving Seniors Timely Access to Care Act of 2021 * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Policies that impact public programs payments for high cost drugs including gene therapies. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* H.R 2166/S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173, the Improving Seniors Timely Access to Care Act of 2021. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Policies that impact Medicare vision, dental, and hearing benefits. * Policies that impact public programs payments for high cost drugs including gene therapies. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. Con Res 14 and the impact on the expansion of Medicare benefits.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173/S.3018, the Improving Seniors Timely Access to Care Act of 2021 * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173/S.3018, the Improving Seniors Timely Access to Care Act of 2021 * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Lower Costs, More Cures Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to S.909, The Prescription Drug Price Relief Act; S. 908, The Medicare Drug Price Negotiation Act; and S. 920, The Affordable and Safe Prescription Drug Importation Act. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues retated to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
Lower Costs, More Cures Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Improving Seniors’ Timely Access to Care Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173/S.3018, the Improving Seniors Timely Access to Care Act of 2021 * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Improving Seniors’ Timely Access to Care Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173/S.3018, the Improving Seniors Timely Access to Care Act of 2021 * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Telehealth Modernization Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Telehealth Modernization Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021.
* Issues related to S. 1720/H.R. 3076, the Postal Service Reform Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
* Issues related to S. 1720/H.R. 3076, the Postal Service Reform Act of 2022.
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074, To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
* Issues related to S. 1720/H.R. 3076, the Postal Service Reform Act of 2021.
* S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173/S.3018, the Improving Seniors Timely Access to Care Act of 2021 * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
* S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173/S.3018, the Improving Seniors Timely Access to Care Act of 2021 * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
* Issues related to S. 1720/H.R. 3076, the Postal Service Reform Act of 2021.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
* H.R 2166/S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173, the Improving Seniors Timely Access to Care Act of 2021. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Policies that impact Medicare vision, dental, and hearing benefits. * Policies that impact public programs payments for high cost drugs including gene therapies. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. Con Res 14 and the impact on the expansion of Medicare benefits.
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
* H.R 2166/S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. * H.R. 2608, the Ensuring Seniors Access to Local Pharmacies Act of 2021. * H.R. 2846, the Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173, the Improving Seniors Timely Access to Care Act of 2021 * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Policies that impact public programs payments for high cost drugs including gene therapies. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to S.909, The Prescription Drug Price Relief Act; S. 908, The Medicare Drug Price Negotiation Act; and S. 920, The Affordable and Safe Prescription Drug Importation Act. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues retated to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE